Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 7/20 | 0.44 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2848040 | 1.00 | PYGB (0.44) | PYGBCA2CA9CA12CA1 | |
| SCHEMBL4006332 | 1.00 | PYGB (0.44) | PYGBCA2CA9CA12CA1 | |
| SCHEMBL29550937 | 0.87 | PYGB (0.49) | PYGBCA2CA9CA12CA1 | |
| SCHEMBL1903565 | 0.87 | PYGB (0.41) | PYGBCA2CA9CA12CA1 | |
| SCHEMBL20817264 | 0.87 | PYGB (0.41) | PYGBCA2CA9CA12CA1 | |
| SCHEMBL23066316 | 0.87 | PYGB (0.41) | PYGBCA2CA9CA12CA1 | |
| SCHEMBL20476841 | 0.86 | PYGB (0.51) | PYGBCA2CA9CA12CA1 | |
| SCHEMBL3801496 | 0.86 | PYGB (0.51) | PYGBCA2CA9CA12CA1 | |
| SCHEMBL2012475 | 0.86 | PYGB (0.51) | PYGBCA2CA9CA12CA1 | |
| SCHEMBL28419458 | 0.86 | PYGB (0.51) | PYGBCA2CA9CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313163-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Ambrx, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022212899-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | AMBRX, INC. (US) | 2022-10-06 | — | — | WO | disclosed |
| EP-3983410-A1 | 1-(4-(AMINOMETHYL)BENZYL)-2-BUTYL-2H-PYRAZOLO[3,4-C]QUINOLIN-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR) 7/8 AGONISTS, AS WELL AS ANTIBODY DRUG CONJUGATES THEREOF FOR USE IN CANCER THERAPY AND DIAGNOSIS | Sutro Biopharma, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| EP-3923991-A1 | COMPOSITIONS CONTAINING, METHODS AND USES OF ANTIBODY-TLR AGONIST CONJUGATES | Ambrx, Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| WO-2020257235-A1 | 1-(4-(AMINOMETHYL)BENZYL)-2-BUTYL-2H-PYRAZOLO[3,4-C]QUINOLIN-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR) 7/8 AGONISTS, AS WELL AS ANTIBODY DRUG CONJUGATES THEREOF FOR USE IN CANCER THERAPY AND DIAGNOSIS | SUTRO BIOPHARMA, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020252015-A1 | IMMUNOMODULATOR ANTIBODY DRUG CONJUGATES AND USES THEREOF | SUTRO BIOPHARMA, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020168017-A1 | COMPOSITIONS CONTAINING, METHODS AND USES OF ANTIBODY-TLR AGONIST CONJUGATES | AMBRX, INC. (US) | 2020-08-20 | — | — | WO | disclosed |
| EP-3658588-A1 | METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN TREATMENT OF T-CELL LYMPHOMA | Sutro Biopharma, Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-3538546-A1 | COMPOSITIONS, METHODS, AND THERAPEUTIC USES RELATED TO FUSOGENIC PROTEIN MINION | Novartis AG (CH) | 2019-09-18 | — | — | EP | disclosed |
| EP-3538127-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CARTILAGE DAMAGE AND ARTHRITIS | Novartis AG (CH) | 2019-09-18 | — | — | EP | disclosed |
| EP-2247743-A2 | MODIFIED LEPTIN POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2010-11-10 | — | — | EP | disclosed |
| EP-2217265-A2 | MODIFIED INSULIN POLYPEPTIDES AND THEIR USES | Ambrx, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2010006214-A1 | FGF-21 NEUTRALIZING ANTIBODIES AND THEIR USES | AMBRX, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| WO-2009117622-A2 | MODIFIED FGF-23 POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009100255-A2 | MODIFIED LEPTIN POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009067636-A2 | MODIFIED INSULIN POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009052435-A1 | ANTI-TNFRI POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2009-04-23 | — | — | WO | disclosed |
| EP-1771205-A4 | NOVEL ANTIGEN-BINDING POLYPEPTIDES AND THEIR USES | AMBRX INC (US) | 2008-10-01 | — | — | EP | disclosed |
| EP-1771205-A2 | NOVEL ANTIGEN-BINDING POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006009901-A2 | NOVEL ANTIGEN-BINDING POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2006-01-26 | — | — | WO | disclosed |